Figure 6.

Clinical impacts of DDX41 germ line and somatic variants. (A) Cumulative incidence of leukemic progression in MNs patients with P/LP germ line truncating/nontruncating DDX41 variants, those with somatic alone, and those without any DDX41 mutation. (B) Kaplan-Meier curves of OS in MDS with and without DDX41 mutations (truncating and nontruncating variants). LR- and HR-MDS were separately shown. (C) Kaplan-Meier curves of OS depending on disease subtype and IPSS-R. Patients with or without any DDX41 mutations were separately shown. (D) Kaplan-Meier curves of OS in MDS, MDS/MPN, and sAML depending on the allelic status of TP53 and the presence of DDX41 mutations. Patients not examined by copy-number analysis, for whom the allelic status of TP53 could not be determined, were excluded from the analysis. P values are provided using Gray test in panel A, and the log-rank test in panels B-D.